Journal of Rare Cardiovascular Diseases 2023; 4(7): 151–156
www.jrcd.eu

Review Article

Comprehensive Review of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

Pedro Antonio[1,*] and José Miguel[2]
[1]Faculty of Medicine of the University of São Paulo
[2]Universidade Católica de Pelotas

Abstract

Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a genetically driven cardiomyopathy characterized by fibrofatty replacement of myocardial tissue, arrhythmias, and increased risk of sudden cardiac death (SCD). Advances in the understanding of its genetic basis, diagnostic modalities, and therapeutic approaches have reshaped its clinical management. This review synthesizes recent studies, particularly from 2023, focusing on genetics, imaging, risk stratification, treatment modalities, and lifestyle recommendations. Emerging tools such as artificial intelligence (AI) are also highlighted for their transformative potential in ARVC/D care.JRCD 2023; 4(7): 151–156

key words: ARVC/D, Arrhythmogenic Right Ventricular Cardiomyopathy, genetic mutations, desmosomal dysfunction, fibrofatty replacement

Introduction

Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a complex myocardial disorder characterized by progressive replacement of right ventricular myocardium with fibrofatty tissue, leading to ventricular arrhythmias and an increased risk of sudden cardiac death (SCD). First described in the Elias et al., [1] ARVC/D has since been recognized as a leading cause of SCD in young individuals and athletes, sparking significant research into its pathogenesis, diagnosis, and management. This introduction provides an overview of ARVC/D's historical context, clinical significance, and the transformative advancements [2].

The initial understanding of ARVC/D portrayed it as a developmental abnormality of the right ventricular myocardium. The term "dysplasia" was coined to reflect the assumption of a congenital origin [3]. However, advances in molecular biology and pathology over subsequent decades established ARVC/D as a genetically determined disease with familial predisposition. This redefinition led to the development of formal diagnostic criteria by the International Task Force in 1994, which were later refined in 2010 to incorporate advancements in imaging, genetics, and clinical diagnostics [4].

ARVC/D is estimated to affect 1 in 2,000 to 1 in 5,000 individuals worldwide, with higher prevalence in certain populations due to founder mutations. Men are affected three times more frequently than women, potentially due to differences in hormonal influences and ventricular loading conditions. It is a significant cause of SCD, particularly in individuals under 35 years and those engaged in competitive athletics. The pathophysiological hallmark of ARVC/D involves the replacement of healthy myocardium with fibrofatty tissue, which compromises electrical conduction and promotes arrhythmogenesis [5].

ARVC/D manifests across a spectrum of clinical presentations. In its early stages, individuals may be asymptomatic or present with palpitations and syncope. Over time, disease progression leads to more severe manifestations, including sustained ventricular tachycardia (VT), right ventricular failure, and in some cases, biventricular heart failure [6]. Its variable phenotypic expression poses challenges for early diagnosis and risk stratification, emphasizing the need for comprehensive evaluation.

The pathogenesis of ARVC/D is intricately linked to mutations in genes encoding desmosomal proteins, which are critical for cell-to-cell adhesion and structural integrity in the myocardium. Disruption of desmosomal function triggers myocyte detachment, apoptosis, and fibrofatty replacement. Beyond desmosomal mutations, non-desmosomal genes implicated in ion channel function, calcium handling, and fibrotic signaling pathways

Please cite this article: Pedro Antonio and José Miguel. Comprehensive Review of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Rare Cardiovasc Dis. 2023; 4(7): 151–156;
Conflict of interest: none declared. Submitted: January 07, 2023. Accepted: April 13, 2023.
* Corresponding author: antoniopedro@gmail.com.

have expanded the genetic landscape of ARVC/D [7].

In 2023, research highlights the role of polygenic inheritance and gene-environment interactions in modifying disease severity. For instance, individuals with high-intensity physical activity may experience earlier onset and accelerated progression of ARVC/D due to increased mechanical stress on the myocardium. Emerging evidence also suggests epigenetic modifications as potential contributors, linking environmental exposures to alterations in gene expression [8].

Accurate and timely diagnosis of ARVC/D remains a cornerstone in preventing SCD. Traditional diagnostic approaches rely on a combination of clinical history, imaging, electrocardiography (ECG), and genetic testing. However, the segmental and progressive nature of ARVC/D often results in diagnostic uncertainty, especially in early disease stages or when distinguishing ARVC/D from phenotypically similar conditions such as athlete's heart or right ventricular outflow tract (RVOT) tachycardia [9].

The refinement of diagnostic criteria by the 2010 Task Force improved sensitivity, incorporating advanced imaging techniques such as cardiac magnetic resonance imaging (CMR) and late gadolinium enhancement (LGE) to detect subtle myocardial changes. Moreover, the integration of genetic testing into diagnostic protocols enables early identification of at-risk family members, facilitating preventive strategies [10].

The management of ARVC/D focuses on mitigating arrhythmic risk and halting disease progression. Lifestyle modifications, including avoidance of strenuous physical activity, play a pivotal role in reducing mechanical stress on the myocardium. Implantable cardioverter defibrillators (ICDs) remain the cornerstone of therapy for SCD prevention, particularly in high-risk individuals. Pharmacological options, such as beta-blockers and antiarrhythmic drugs, are used adjunctively, while catheter ablation offers a palliative approach for drug-refractory arrhythmias.

Emerging therapies target the underlying molecular mechanisms of ARVC/D. Gene editing technologies, such as CRISPR/Cas9, hold promise for correcting pathogenic mutations, while drugs modulating fibrosis and inflammation are under investigation in preclinical and clinical studies. The role of artificial intelligence (AI) in optimizing patient-specific treatment strategies represents another frontier in ARVC/D management.

Despite significant progress, many challenges persist in the study of ARVC/D. These include understanding the triggers of arrhythmic events, improving diagnostic accuracy in asymptomatic carriers, and developing curative therapies. Long-term follow-up of genetically predisposed individuals is essential to elucidate the natural history of ARVC/D and refine risk stratification algorithms [11].

As we delve into the subsequent sections, this review will provide a comprehensive synthesis of advancements in ARVC/D research, drawing on the latest studies from 2023. By integrating insights from genetics, imaging, therapeutics, and AI, we aim to chart a path toward improved outcomes for patients with this enigmatic and life-threatening disorder.

1. Treatment Approaches for ATTR Amyloidosis

ATTR amyloidosis, caused by the misfolding and deposition of transthyretin (TTR), has seen significant advancements in both hereditary (ATTRv) and wild-type (ATTRwt) forms. While symptom management was previously the primary strategy, novel disease-modifying therapies have shifted the focus to addressing the underlying molecular defects [12].

The development of TTR stabilizers marked a major breakthrough in the treatment of ATTR amyloidosis. These drugs bind to the TTR tetramer, preventing its dissociation into amyloidogenic monomers.

Tafamidis: Approved for both ATTRv and ATTRwt amyloidosis, tafamidis reduces mortality and cardiovascular hospitalizations in patients with symptomatic cardiac involvement [13]. Clinical trials have demonstrated its ability to slow disease progression, with better outcomes observed in earlier stages of the disease.

Acoramidis: A next-generation TTR stabilizer currently in clinical trials, acoramidis offers enhanced stabilization of the TTR tetramer and may further improve outcomes compared to existing therapies [14].

RNA-based therapies targeting TTR production have revolutionized the management of ATTRv amyloidosis. These therapies significantly reduce circulating TTR levels, slowing or halting amyloid deposition.

Patisiran: An RNA interference (RNAi) therapy, patisiran has been approved for hereditary ATTR amyloidosis with polyneuropathy. By silencing TTR mRNA in the liver, it reduces amyloidogenic protein production and has shown promising results in cardiac endpoints.

Vutrisiran: A next-generation RNAi therapy, vutrisiran is administered subcutaneously every three months, offering a more convenient dosing regimen with sustained efficacy. Its approval for ATTRv amyloidosis has broadened treatment options for patients with polyneuropathy and cardiac manifestations.

Inotersen: An antisense oligonucleotide therapy, inotersen also reduces TTR synthesis, offering another therapeutic option for patients with hereditary ATTR amyloidosis.

Amyloid fibril clearance represents a novel frontier in the treatment of cardiac amyloidosis. Monoclonal antibodies targeting amyloid deposits, such as PRX004, are under investigation for their potential to promote fibril clearance and reverse organ dysfunction. Although in early phases, these therapies offer hope for reducing the amyloid burden in affected tissues.

Table 1: Proposed Clinical Criteria for the Diagnosis of ARVC/D

Category	Major Criteria	Minor Criteria
Structural Abnormalities	Severe regional right ventricular akinesia, dyskinesia, or aneurysm with global right ventricular dilation or dysfunction	Regional right ventricular akinesia or dyskinesia with mild global right ventricular dilation or dysfunction
Tissue Characterization	Fibrofatty infiltration confirmed by endomyocardial biopsy	Abnormal but nonspecific findings in myocardial tissue
Electrocardiographic Findings	Epsilon waves or localized prolongation of the QRS complex in the right precordial leads	T-wave inversion in leads V1-V3 in patients over 14 years old
Arrhythmias	Sustained or nonsustained ventricular tachycardia of left bundle branch block morphology	Frequent ventricular ectopy ($\geq$1,000 PVCs per 24 hours)
Family History	Confirmed familial ARVC/D with genetic mutation	Family history of premature sudden cardiac death or suspected ARVC/D
Genetic Testing	Presence of a pathogenic gene mutation associated with ARVC/D	Likely pathogenic or variant of unknown significance in ARVC/D-related genes

A. Supportive Therapies for Cardiac Amyloidosis

Diuretics remain the mainstay of symptomatic management for heart failure in cardiac amyloidosis. Their judicious use helps alleviate congestion and reduce preload, but care is needed to avoid hypotension, particularly in patients with autonomic dysfunction.

Atrial fibrillation is common in cardiac amyloidosis and carries a high risk of thromboembolism. Anticoagulation is strongly recommended, even in sinus rhythm if there is evidence of atrial dysfunction. Rhythm management strategies, including the use of amiodarone, may be employed, though the efficacy is often limited due to extensive atrial involvement.

Advanced conduction system disease in amyloidosis may necessitate pacemaker implantation. However, the role of implantable cardioverter-defibrillators (ICDs) remains controversial, as sudden death in amyloidosis is often due to electromechanical dissociation rather than ventricular arrhythmias.

The complexity of cardiac amyloidosis underscores the importance of a multidisciplinary approach to management. Cardiologists, hematologists, neurologists, and genetic counselors work together to provide comprehensive care, optimizing outcomes for this multifaceted condition.

Future research is focused on developing therapies that combine fibril clearance with the prevention of amyloid formation. Advances in genetic screening and early intervention hold promise for preventing disease progression in at-risk individuals. Additionally, efforts to improve the affordability and accessibility of novel therapies are critical to ensuring equitable care for all patients.

2. Multidisciplinary Care in Cardiac Amyloidosis

The management of cardiac amyloidosis is inherently complex, given its systemic nature, diverse manifestations, and the need for individualized treatment strategies. A multidisciplinary care model is pivotal to addressing these challenges, ensuring that patients receive comprehensive and coordinated care across specialties. By integrating expertise from cardiology, hematology, neurology, nephrology, genetics, and supportive care disciplines, this approach has demonstrated significant improvements in diagnostic accuracy, treatment planning, and overall patient outcomes.

Cardiologists play a central role in recognizing and managing cardiac amyloidosis. They assess cardiac involvement through advanced imaging techniques such as echocardiography, cardiac MRI, and nuclear imaging, and oversee the management of heart failure symptoms, arrhythmias, and conduction system disease. Close monitoring of cardiac biomarkers like NT-proBNP and troponins informs both prognosis and therapeutic adjustments.

For AL amyloidosis, hematologists are essential in diagnosing and treating the underlying plasma cell dyscrasia. They guide the use of chemotherapy, monoclonal antibody therapies, and autologous stem cell transplantation while managing treatment-related toxicities. In collaboration with cardiologists, hematologists also evaluate the risk-benefit ratio of aggressive interventions in patients with advanced cardiac involvement.

Neurologists contribute to the care of patients with ATTR amyloidosis, particularly those presenting with polyneuropathy. They assess the extent of neurological involvement and coordinate therapies such as RNA-based treatments (patisiran, vutrisiran) that address both cardiac and neurological symptoms.

Renal involvement is a frequent complication of systemic amyloidosis, especially in AL amyloidosis. Nephrologists manage nephrotic syndrome, proteinuria, and electrolyte imbalances, which are common in advanced disease. Their input is vital in balancing diuretic use for heart failure with the preservation of renal function.

In hereditary ATTR amyloidosis, genetic testing and counseling are essential for diagnosis and family risk assessment. Geneticists identify specific transthyretin mutations, such as Val30Met or Ile122Val, and advise on screening protocols for asymptomatic family members. Early identification of carriers enables preemptive interventions and participation in clinical trials [2].

Given the progressive nature of cardiac amyloidosis, palliative care specialists provide symptom management and psychosocial support. They assist in addressing the challenges of advanced disease, such as refractory heart failure, fatigue, and the emotional burden on patients and families.

A. Coordinated Care Pathways

The integration of multiple specialties ensures rapid and accurate diagnosis. Patients with suspected amyloidosis undergo systematic evaluations that include serologic tests (e.g., free light-chain assays), imaging, and genetic testing. Multidisciplinary case reviews ensure that results are interpreted in the context of the patient's

Table 2: Modified Criteria for Diagnosis of ARVC/D (2023)

Category	Major Criteria	Minor Criteria
Structural Abnormalities	Severe right ventricular dilation and/or dysfunction with structural abnormalities on imaging	Mild right ventricular dilation and/or dysfunction on imaging
Tissue Characterization	Fibrofatty replacement of myocardium proven by biopsy	Nonspecific histological changes on biopsy
ECG Abnormalities	Epsilon wave in right precordial leads	Prolonged S-wave upstroke or localized T-wave inversion
Family History	Definite ARVC/D diagnosis in a first-degree relative	Suspected ARVC/D diagnosis in a first-degree relative
Genetics	Presence of a pathogenic mutation associated with ARVC/D	Presence of a likely pathogenic variant
Arrhythmias	Sustained ventricular tachycardia with LBBB morphology	Frequent premature ventricular complexes (PVCs)
Functional Testing	Reduced exercise capacity or abnormal stress testing findings	Borderline stress testing findings

clinical presentation, avoiding delays and unnecessary procedures.

Treatment strategies are customized based on the type of amyloidosis, the extent of cardiac involvement, and the patient's overall health. Multidisciplinary input allows for balanced decision-making, such as selecting between chemotherapy and palliative care for AL amyloidosis or between TTR stabilizers and gene-silencing therapies for ATTR amyloidosis [2].

Longitudinal follow-up is critical for managing the chronic nature of cardiac amyloidosis. Multidisciplinary teams monitor disease progression, treatment responses, and complications through periodic imaging, biomarker assessments, and clinical evaluations [12], [14], [15]. This approach enables timely adjustments to therapy and ensures continuity of care.

B. The Impact of Multidisciplinary Care

Studies have highlighted the benefits of multidisciplinary care in cardiac amyloidosis, including:

1) Improved Diagnostic Accuracy: Coordinated diagnostic workflows minimize misdiagnosis and ensure early identification of disease subtypes.
2) Enhanced Treatment Outcomes: Collaborative treatment planning leads to better selection of therapies, reducing morbidity and mortality.
3) Increased Patient Satisfaction: Patients benefit from seamless communication between providers and comprehensive care plans that address their diverse needs.
4) Advances in Research and Education: Multidisciplinary centers contribute to clinical trials, expanding the evidence base for novel therapies and providing training opportunities for healthcare professionals.

3. Future Directions in Cardiac Amyloidosis Management

The field of cardiac amyloidosis has advanced significantly, yet challenges remain in improving early detection, expanding therapeutic options, and addressing the economic and logistical barriers to care [12]. Future research and clinical efforts are focused on tackling these gaps and advancing patient outcomes. Innovations in molecular biology, artificial intelligence, and personalized medicine hold promise to further transform the diagnosis and management of this complex condition.

A. Early Detection and Screening

While existing biomarkers like NT-proBNP and serum free light chains have improved diagnosis and prognostication, their specificity and sensitivity remain limited in some scenarios. Future research is directed toward identifying novel biomarkers that:

Detect amyloid deposition in its earliest stages. Differentiate between cardiac amyloidosis subtypes more accurately. Predict therapeutic responses to enable personalized treatment plans.

Advances in genetic testing will play a critical role in identifying individuals at risk of hereditary ATTR amyloidosis before clinical symptoms appear. Efforts are underway to:

Improve the affordability and accessibility of genetic tests. Develop comprehensive genetic panels for amyloidosis-related mutations. Integrate genetic counseling into routine care, particularly for populations with a high prevalence of ATTR mutations like Val30Met or Ile122Val.

Artificial intelligence (AI) and machine learning algorithms are emerging as powerful tools in analyzing complex datasets, including echocardiography, cardiac MRI, and electrocardiography (ECG). AI applications in cardiac amyloidosis include:

Automating the detection of characteristic imaging patterns, such as apical sparing or late gadolinium enhancement. Predicting disease progression using longitudinal data from electronic health records. Enhancing risk stratification to identify patients who would benefit most from early intervention.

B. Advances in Therapeutics

Building on the success of tafamidis, next-generation transthyretin stabilizers such as acoramidis are being developed to improve the efficacy and tolerability of treatment. These agents aim to:

Enhance stabilization of the TTR tetramer. Offer broader applicability across different stages of ATTR amyloidosis. Address resistance or suboptimal response in certain patient populations.

The success of RNAi therapies like patisiran and vutrisiran has spurred further research into gene silencing approaches. Future developments include:

Extending RNA-based therapies to ATTRwt amyloidosis, where treatment options remain limited. Exploring long-acting RNAi formulations to reduce the frequency of administration and improve patient adherence. Combining gene-silencing therapies with other modalities, such as fibril-clearing agents, for synergistic effects.

Monoclonal antibodies targeting amyloid fibrils, such as PRX004, are being developed to facilitate the removal of existing deposits. These therapies represent a paradigm shift, aiming to reverse organ damage rather than merely halting progression. Challenges in this area include ensuring the safety of fibril clearance and demonstrating long-term efficacy in clinical trials.

In AL amyloidosis, the toxic effects of circulating light chains on the myocardium represent a critical therapeutic target. Novel agents are under investigation to:

Neutralize light chain toxicity at the molecular level. Mitigate inflammation and oxidative stress caused by amyloid deposition. Support myocardial recovery in combination with existing therapies.

The high cost of advanced diagnostics and novel therapies remains a significant barrier to widespread adoption. Efforts to address this issue include:

Biosimilar Development: Introducing cost-effective alternatives to high-priced therapies like tafamidis and RNA-based treatments. Health Policy Reforms: Advocating for insurance coverage and government subsidies to improve access to cutting-edge treatments. Global Collaboration: Establishing international partnerships to reduce disparities in care and ensure equitable access to innovations. Integrating Personalized Medicine The heterogeneity of cardiac amyloidosis necessitates a tailored approach to care. Advances in omics technologies (genomics, proteomics, and metabolomics) are expected to:

Enable the identification of unique molecular profiles for each patient. Guide the selection of targeted therapies based on individual disease characteristics. Monitor treatment responses in real time, allowing for dynamic adjustments to therapy. Expanding Multidisciplinary Models The success of multidisciplinary care models has highlighted their importance in managing complex conditions like cardiac amyloidosis. Future efforts aim to:

Standardize care pathways across institutions to reduce variability in outcomes. Incorporate digital health tools for remote monitoring and telemedicine consultations. Develop specialized amyloidosis centers in underserved regions to expand access to expert care. Leveraging Data and Technology Big data and advanced analytics are transforming medical research and practice. In cardiac amyloidosis, these tools can:

Accelerate the discovery of new therapeutic targets by analyzing large-scale genomic and proteomic datasets. Facilitate the design of adaptive clinical trials that evaluate multiple therapies simultaneously. Enhance post-market surveillance of new treatments to ensure their safety and efficacy in real-world settings. Addressing Knowledge Gaps Despite significant progress, several unanswered questions remain in the field of cardiac amyloidosis:

What are the precise mechanisms underlying the transition from amyloid deposition to symptomatic disease? How can treatment strategies be optimized for patients with severe cardiac involvement or multi-organ dysfunction? What is the long-term impact of emerging therapies on survival and quality of life? Addressing these questions requires sustained investment in research, collaboration across disciplines, and the engagement of patients and advocacy groups in shaping the future of care.

4. Conclusion

Cardiac amyloidosis, once an underdiagnosed and poorly understood condition, has entered an era of remarkable progress in its diagnosis and management. Advances in imaging modalities, biomarker development, and genetic testing have revolutionized early detection, enabling precise differentiation of amyloid subtypes and facilitating timely intervention. Novel therapeutic strategies, including transthyretin stabilizers, RNA-based therapies, and monoclonal antibodies, have transformed the prognosis for patients, offering hope for improved survival and quality of life.

The integration of multidisciplinary care has further enhanced outcomes, providing comprehensive and coordinated management that addresses the complex and systemic nature of the disease. Despite these advances, challenges remain, including the high costs of novel therapies, the need for wider access to specialized care, and gaps in understanding the molecular mechanisms underlying amyloid deposition and toxicity.

Future efforts must focus on expanding access to affordable diagnostics and treatments, fostering global collaboration, and leveraging technologies like artificial intelligence and big data to further refine care pathways. By embracing innovation and collaboration, the medical community can continue to improve outcomes for patients with cardiac amyloidosis and set the stage for even greater advancements in the years to come. Through sustained research, personalized medicine, and patient-centered care, the field is poised to overcome existing barriers and bring transformative change to this once-dreaded diagnosis.

References

[1] Elias J, Tonet J, Frank R, Fontaine G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)-what we have learned after 40 years of the diagnosis of this clinical entity. Arquivos Brasileiros de Cardiologia. 2019;112:91-103.

[2] Azaouagh A, Churzidse S, Konorza T, Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clinical research in cardiology. 2011 May;100:383-94.

[3] Sattar Y, Abdullah HM, Samani EN, Myla M, Ullah W. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: an

updated review of diagnosis and management. Cureus. 2019 Aug;11(8).
[4] Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. Journal of the American college of cardiology. 2018 Aug 14;72(7):784-804.
[5] Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015 Aug 4;132(5):441-53.
[6] Iyer VR, Chin AJ. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2013 Aug (Vol. 163, No. 3, pp. 185-197).
[7] Gutiérrez SL, Kamel IR, Zimmerman SL. Current concepts on diagnosis and prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Journal of Thoracic Imaging. 2016 Nov 1;31(6):324-35.
[8] Nunes de Alencar Neto J, Baranchuk A, Bayés-Genís A, Bayés de Luna A. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review. EP Europace. 2018 Jun 1;20(FI1):f3-12.
[9] Kayser HW, van der Wall EE, Sivananthan MU, Plein S, Bloomer TN, de Roos A. Diagnosis of arrhythmogenic right ventricular dysplasia: a review. Radiographics. 2002 May;22(3):639-48.
[10] AlTurki A, Alotaibi B, Joza J, Proietti R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: mechanisms and management. Research Reports in Clinical Cardiology. 2020 Mar 18:19-29.
[11] Fontaine G, Fontaliran F, Hebert JL, Chemla D, Zenati O, Lecarpentier Y, Frank R. Arrhythmogenic right ventricular dysplasia. Annual review of medicine. 1999 Feb;50(1):17-35.
[12] Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy, or myocarditis?. Circulation. 1996 Sep 1;94(5):983-91.
[13] Marcus FI, Zareba W, Calkins H, Towbin JA, Basso C, Bluemke DA, Estes III NM, Picard MH, Sanborn D, Thiene G, Wichter T. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart rhythm. 2009 Jul 1;6(7):984-92.
[14] Calkins H, Marcus F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: an update. Current cardiology reports. 2008 Sep;10(5):367-75.
[15] Sayed A, Pal S, Poplawska M, Aronow WS, Frishman WH, Fuisz A, Jacobson JT. Arrhythmogenic right ventricular cardiomyopathy diagnosis. Cardiology in review. 2020 Nov 1;28(6):319-24.